Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Toxicol Appl Pharmacol ; 196(2): 266-86, 2004 Apr 15.
Article in English | MEDLINE | ID: mdl-15081273

ABSTRACT

2,4-Dithiobiuret (DTB) causes ascending motor weakness when given chronically to rodents. In muscles of animals with DTB-induced weakness, quantal release of acetylcholine (ACh) is impaired. We examined in detail the structural changes that occurred at neuromuscular junctions and their associated Schwann cells of extensor digitorum longus (EDL) muscles of male rats treated with DTB to the onset of muscle weakness, 5-8 days. Our objective was to assess the involvement of the Schwann cells and to determine the most likely primary targets of DTB. At the onset of muscle weakness, nerve terminals exhibited some enlarged regions, but did not sprout. Terminal Schwann cells became flatter and expanded to cover most of the endplate. The extent of invasion of the synaptic cleft by Schwann cell processes was not significantly different from controls; extension of Schwann cell sprouts away from the junction was not seen. Thus, the morphology of the Schwann cells, although clearly affected by DTB, does not suggest that they contribute directly to the physiological defects of DTB-treated terminals. Abnormal tubulovesicular structures or tangles of neurofilaments were clustered in the centers of about 25% of treated terminals. Fewer synaptic vesicles occupied the region opposite the postsynaptic folds. Vesicle volumes were variable and included some very large vesicles, corresponding with the variable MEPP amplitudes reported previously for terminals of DTB-treated rodents. The postsynaptic area stained by rhodamine-labeled alpha-bungarotoxin expanded with terminal swelling, apparently by unpleating of the postsynaptic folds. No loss of ACh receptors or spread of ACh receptors beyond terminal boundaries was detected. Morphometric data are consistent with the conclusion that DTB affects, either directly or indirectly, vesicular release of ACh and the subsequent vesicular recycling process.


Subject(s)
Muscle Weakness/chemically induced , Muscle, Skeletal/drug effects , Nerve Endings/drug effects , Neuromuscular Junction/physiopathology , Thiourea/analogs & derivatives , Thiourea/poisoning , Animals , Bungarotoxins/chemistry , Coloring Agents/chemistry , Evoked Potentials/physiology , Male , Mice , Mice, Inbred ICR , Microscopy, Electron, Scanning , Microscopy, Fluorescence , Muscle Weakness/physiopathology , Muscle, Skeletal/anatomy & histology , Muscle, Skeletal/physiopathology , Nerve Endings/physiopathology , Neuromuscular Junction/anatomy & histology , Nitroblue Tetrazolium/chemistry , Pyridinium Compounds/chemistry , Quaternary Ammonium Compounds/chemistry , Rats , Rats, Sprague-Dawley , Schwann Cells/drug effects , Schwann Cells/metabolism , Schwann Cells/pathology
2.
J Neurophysiol ; 88(6): 3243-58, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12466444

ABSTRACT

Chronic treatment of rodents with 2,4-dithiobiuret (DTB) induces a neuromuscular syndrome of flaccid muscle weakness that mimics signs seen in several human neuromuscular disorders such as congenital myasthenic syndromes, botulism, and neuroaxonal dystrophy. DTB-induced muscle weakness results from a reduction of acetylcholine (ACh) release by mechanisms that are not yet clear. The objective of this study was to determine if altered release of ACh during DTB-induced muscle weakness was due to impairments of synaptic vesicle exocytosis, endocytosis, or internal vesicular processing. We examined motor nerve terminals in the triangularis sterni muscles of DTB-treated mice at the onset of muscle weakness. Uptake of FM1-43, a fluorescent marker for endocytosis, was reduced to approximately 60% of normal after either high-frequency nerve stimulation or K(+) depolarization. Terminals ranged from those with nearly normal fluorescence ("bright terminals") to terminals that were poorly labeled ("dim terminals"). Ultrastructurally, the number of synaptic vesicles that were labeled with horseradish peroxidase (HRP) was also reduced by DTB to approximately 60%; labeling among terminals was similarly variable. A subset of DTB-treated terminals having abnormal tubulovesicular profiles in their centers did not respond to stimulation with increased uptake of HRP and may correspond to dim terminals. Two findings suggest that posttetanic "slow endocytosis" remained qualitatively normal: the rate of this type of endocytosis as measured with FM1-43 did not differ from normal, and HRP was observed in organelles associated with this pathway- coated vesicles, cisternae, as well as synaptic vesicles but not in the tubulovesicular profiles. In DTB-treated bright terminals, end-plate potential (EPP) amplitudes were decreased, and synaptic depression in response to 15-Hz stimulation was increased compared with those of untreated mice; in dim terminals, EPPs were not observed during block with D-tubocurarine. Nerve-stimulation-induced unloading of FM1-43 was slower and less complete than normal in bright terminals, did not occur in dim terminals, and was not enhanced by alpha-latrotoxin. Collectively, these results indicate that the size of the recycling vesicle pool is reduced in nerve terminals during DTB-induced muscle weakness. The mechanisms by which this reduction occurs are not certain, but accumulated evidence suggests that they may include defects in either or both exocytosis and internal vesicular processing.


Subject(s)
Exocytosis/physiology , Neuromuscular Junction/drug effects , Neuromuscular Junction/physiology , Synaptic Vesicles/physiology , Thiourea/analogs & derivatives , Thiourea/pharmacology , Animals , Fluorescent Dyes , Horseradish Peroxidase/metabolism , Horseradish Peroxidase/pharmacokinetics , Male , Mice , Mice, Inbred ICR , Nerve Endings/drug effects , Nerve Endings/metabolism , Nerve Endings/ultrastructure , Oxidation-Reduction/drug effects , Pyridinium Compounds , Quaternary Ammonium Compounds , Spider Venoms/pharmacology , Staining and Labeling , Synaptic Transmission/drug effects , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...